Literature DB >> 29053189

Pilot screening study of targeted genetic polymorphisms for association with seasonal influenza hospital admission.

Tonia C Carter1, Scott J Hebbring1, Jixia Liu1, Jonathan D Mosley2, Christian M Shaffer2, Lynn C Ivacic3, Sarah Kopitzke4, Elisha L Stefanski3, Rob Strenn5, Maria E Sundaram4, Jennifer Meece3, Murray H Brilliant1, Jill M Ferdinands6, Edward A Belongia4.   

Abstract

Host response to influenza is highly variable, suggesting a potential role of host genetic variation. To investigate the host genetics of severe influenza in a targeted fashion, 32 single nucleotide polymorphisms (SNPs) within viral immune response genes were evaluated for association with seasonal influenza hospitalization in an adult study population with European ancestry. SNP allele and genotype frequencies were compared between hospitalized influenza patients (cases) and population controls in a case-control study that included a discovery group (26 cases and 993 controls) and two independent, validation groups (1 with 84 cases and 4076 controls; the other with 128 cases and 9187 controls). Cases and controls had similar allele frequencies for variant rs12252 in interferon-inducible transmembrane protein 3 (IFITM3) (P > 0.05), and the study did not replicate the previously reported association of rs12252 with hospitalized influenza. In the discovery group, the preliminary finding of an association with a nonsense polymorphism (rs8072510) within the schlafen family member 13 (SFLN13) gene (P = 0.0099) was not confirmed in either validation group. Neither rs12252 nor rs8072510 showed an association according to the presence of clinical risk factors for influenza complications (P > 0.05), suggesting that these factors did not modify associations between the SNPs and hospitalized influenza. No other SNPs showed a statistically significant association with hospitalized influenza. Further research is needed to identify genetic factors involved in host response to seasonal influenza infection and to assess whether rs12252, a low-frequency variant in Europeans, contributes to influenza severity in populations with European ancestry.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  IFITM3; host susceptibility; influenza; polymorphisms; virus

Mesh:

Substances:

Year:  2017        PMID: 29053189      PMCID: PMC5760323          DOI: 10.1002/jmv.24975

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  40 in total

1.  The International HapMap Project.

Authors: 
Journal:  Nature       Date:  2003-12-18       Impact factor: 49.962

2.  Influenza vaccine effectiveness in Wisconsin during the 2007-08 season: comparison of interim and final results.

Authors:  Edward A Belongia; Burney A Kieke; James G Donahue; Laura A Coleman; Stephanie A Irving; Jennifer K Meece; Mary Vandermause; Stephen Lindstrom; Paul Gargiullo; David K Shay
Journal:  Vaccine       Date:  2011-07-19       Impact factor: 3.641

3.  Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains.

Authors:  John J Treanor; H Keipp Talbot; Suzanne E Ohmit; Laura A Coleman; Mark G Thompson; Po-Yung Cheng; Joshua G Petrie; Geraldine Lofthus; Jennifer K Meece; John V Williams; Lashondra Berman; Caroline Breese Hall; Arnold S Monto; Marie R Griffin; Edward Belongia; David K Shay
Journal:  Clin Infect Dis       Date:  2012-07-25       Impact factor: 9.079

4.  Host genetic variation affects resistance to infection with a highly pathogenic H5N1 influenza A virus in mice.

Authors:  Adrianus C M Boon; Jennifer deBeauchamp; Anna Hollmann; Jennifer Luke; Malak Kotb; Sarah Rowe; David Finkelstein; Geoffrey Neale; Lu Lu; Robert W Williams; Richard J Webby
Journal:  J Virol       Date:  2009-08-12       Impact factor: 5.103

5.  Phosphorylation of the antiviral protein interferon-inducible transmembrane protein 3 (IFITM3) dually regulates its endocytosis and ubiquitination.

Authors:  Nicholas M Chesarino; Temet M McMichael; Jocelyn C Hach; Jacob S Yount
Journal:  J Biol Chem       Date:  2014-03-13       Impact factor: 5.157

6.  Knowledge-driven multi-locus analysis reveals gene-gene interactions influencing HDL cholesterol level in two independent EMR-linked biobanks.

Authors:  Stephen D Turner; Richard L Berg; James G Linneman; Peggy L Peissig; Dana C Crawford; Joshua C Denny; Dan M Roden; Catherine A McCarty; Marylyn D Ritchie; Russell A Wilke
Journal:  PLoS One       Date:  2011-05-11       Impact factor: 3.240

7.  IFITM3 inhibits influenza A virus infection by preventing cytosolic entry.

Authors:  Eric M Feeley; Jennifer S Sims; Sinu P John; Christopher R Chin; Thomas Pertel; Li-Mei Chen; Gaurav D Gaiha; Bethany J Ryan; Ruben O Donis; Stephen J Elledge; Abraham L Brass
Journal:  PLoS Pathog       Date:  2011-10-27       Impact factor: 6.823

8.  Genome-Wide Association Study of Serum Creatinine Levels during Vancomycin Therapy.

Authors:  Sara L Van Driest; Tracy L McGregor; Digna R Velez Edwards; Ben R Saville; Terrie E Kitchner; Scott J Hebbring; Murray Brilliant; Hayan Jouni; Iftikhar J Kullo; C Buddy Creech; Prince J Kannankeril; Susan I Vear; Kyle B Brothers; Erica A Bowton; Christian M Shaffer; Neelam Patel; Jessica T Delaney; Yuki Bradford; Sarah Wilson; Lana M Olson; Dana C Crawford; Amy L Potts; Richard H Ho; Dan M Roden; Josh C Denny
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

9.  Influenza Illness and Hospitalizations Averted by Influenza Vaccination in the United States, 2005-2011.

Authors:  Deliana Kostova; Carrie Reed; Lyn Finelli; Po-Yung Cheng; Paul M Gargiullo; David K Shay; James A Singleton; Martin I Meltzer; Peng-Jun Lu; Joseph S Bresee
Journal:  PLoS One       Date:  2013-06-19       Impact factor: 3.240

10.  Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with severe influenza in Chinese individuals.

Authors:  Yong-Hong Zhang; Yan Zhao; Ning Li; Yan-Chun Peng; Eleni Giannoulatou; Rong-Hua Jin; Hui-Ping Yan; Hao Wu; Jin-Hua Liu; Ning Liu; Da-Yan Wang; Yue-Long Shu; Ling-Pei Ho; Paul Kellam; Andrew McMichael; Tao Dong
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more
  6 in total

Review 1.  Influenza Pathogenesis: The Effect of Host Factors on Severity of Disease.

Authors:  Anshu P Gounder; Adrianus C M Boon
Journal:  J Immunol       Date:  2019-01-15       Impact factor: 5.422

2.  IFITM3 Clusters on Virus Containing Endosomes and Lysosomes Early in the Influenza A Infection of Human Airway Epithelial Cells.

Authors:  Susann Kummer; Ori Avinoam; Hans-Georg Kräusslich
Journal:  Viruses       Date:  2019-06-12       Impact factor: 5.048

3.  Human IFITM3 restricts chikungunya virus and Mayaro virus infection and is susceptible to virus-mediated counteraction.

Authors:  Sergej Franz; Fabian Pott; Thomas Zillinger; Christiane Schüler; Sandra Dapa; Carlo Fischer; Vânia Passos; Saskia Stenzel; Fangfang Chen; Katinka Döhner; Gunther Hartmann; Beate Sodeik; Frank Pessler; Graham Simmons; Jan Felix Drexler; Christine Goffinet
Journal:  Life Sci Alliance       Date:  2021-06-02

Review 4.  Interindividual immunogenic variants: Susceptibility to coronavirus, respiratory syncytial virus and influenza virus.

Authors:  Farzaneh Darbeheshti; Mojdeh Mahdiannasser; Bruce D Uhal; Shuji Ogino; Sudhir Gupta; Nima Rezaei
Journal:  Rev Med Virol       Date:  2021-03-16       Impact factor: 11.043

5.  Antiviral Protection by IFITM3 In Vivo.

Authors:  Ashley Zani; Jacob S Yount
Journal:  Curr Clin Microbiol Rep       Date:  2018-08-03

6.  Association between the interferon-induced transmembrane protein 3 gene (IFITM3) rs34481144 / rs12252 haplotypes and COVID-19.

Authors:  Elías Cuesta-Llavona; Guillermo M Albaiceta; Marta García-Clemente; Israel D Duarte-Herrera; Laura Amado-Rodríguez; Tamara Hermida-Valverde; Ana I Enríquez-Rodriguez; Cristina Hernández-González; Santiago Melón; Marta E Alvarez-Argüelles; José A Boga; Susana Rojo-Alba; Daniel Vázquez-Coto; Juan Gómez; Eliecer Coto
Journal:  Curr Res Virol Sci       Date:  2021-11-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.